CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

Index

AAMC. *See* American Association of Medical Colleges
accordance with existing laws
  in Healthcare Internet of Things design, 145–46
  in TPDA policy, 150
accountability
  as Healthcare Internet of Things design consideration, 144–45
  in TPDA mechanisms, 149–50
ACMG. *See* American College of Medical Genetics and Genomics
active breaches of identity, 185
ad hoc groups, 188
  in analytics, 182
  defined, 187
  identity management for, 185–86, 189–90
ADA. *See* Americans with Disabilities Act
advertisers and advertising, health-related Big Data for, 86
Affordable Care Act, U.S., 211
aggregated data
  in Big Data health care research, 254–55
  HIPAA and, limitations under, 258–59
  sources of, 269
  TPDAs and, 148–49
algorithm patents, 312–14
  in European Union, 313–14
  in U.S., 312–13
algorithmic analytics, 177–79, 182, 266
algorithmic classification, in analytics, 177–79, 182
all-payer claims databases (APCDs), 69, 112–13
  advantages of, 112
  Gobeille v. Liberty Mutual Insurance Co. and, 116–19
  growth of, 113
  pediatric care discrepancies in, 117
  prediction modeling through, 117
American Association of Medical Colleges (AAMC), 258
American College of Medical Genetics and Genomics (ACMG), 202–3
American Recovery and Reinvestment Act, U.S., 102–3
Americans with Disabilities Act (ADA), U.S., 69, 92–96
  data mining practices and, 96
  disability definitions under, 93–96
  discrimination protections under, 71–72
  eligibility criteria for, 93
  GINA and, 93–94
  privacy under, 260
  public accommodations under, 92–93
  "regarded as" provision in, expansion of, 94–96
  scope of, 85
analytics
  ad hoc groups in, 182
  algorithmic classification, 177–79, 182, 266
  behaviors and characteristics in, 175–76
  descriptive classification, 179
  development of, 175
  groups in, ethical significance of, 177–83
  identity in, ethical significance of, 177–83
    offline, 179
    personalization systems, 181–82
    profiling, 179–82
    shared ownership of, 180–81
  predictive classification, 182
  prescriptive classification, 179
  responses to, 175
Anderson, Chris, 50

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

anonymization, of Big Data, 249
  Expert Determination pathway, 281–82
anti-discrimination laws, for group privacy, 187
antimicrobial resistance, decrease of, 56–57
antitrust rules, 320–21
APCDs. *See* all-payer claims databases
Apophenia, 51
ascriptive autonomy, 20
ascriptive groups, 187
assimilation model, defined, 69
autonomy, individual
  ascriptive, 20
  Big Data and, 109
  bioethics and, 20–22. *See also* Common Rule; Health Insurance Portability and Accountability Act Privacy Rule
  IRBs, 20–21
  civic solidarity and, 22
  commonwealths and, formation of, 22
  consumer-driven data commons and, 23–26, 29
    advantages of, 25
    ethical standards of, 25–26
    rules of access for, 24
    value of, 24
  critiques of, 28
  evolution of, 20–22
  Hobbes on, 22
  Kantian notion of, 20
  norm of common purpose, 19–20
  voice as result of, 22–26
  weakness of, 21–22
Avastin, 81–82

Bacon, Francis, 31
best practices
  for Big Data health care research, 254
  Expert Determination pathways and, 280–82
Big Data. *See also* deidentification; health care research; health-related big data; health-related Big Data; intellectual property rights
  analytics of, 158
  anonymization of, 249
  autonomy issues for, 109
  biomedical, 190–91
    genetics research, 190
    implementation of, 191
  collection of, 100–1
    through consumer data, 101–2
    distrust of medical community as factor in, 104
    through EHRs, 98–99, 102–4
    model for, 110–11
  as commodity, 262
  under Common Rule, 28–29, 246–47
    electronic communications and, informed consent in, 246–47
  defined, 1, 252
  ethical guidelines for, 4
  evolution of, 2, 311
  exclusions, 101–6
  FDA discretion over, 107–9
  genomic data flood, 2
  after *Gobeille v. Liberty Mutual Insurance Co.*, 122–23
  health care fraud and, 75–79
    through postmarket analysis, 75
    regulatory requirements, 76–77
  health disparities and, 101–6
    among racial and ethnic minorities, 104–5
  under HIPAA Privacy Rule, 28–29
  as homogeneous, 98–99
  informed consent and, 5
    through electronic communications, 246–47
  integrated sets, 256
  linkage of, from multiple sources, 254
  longitudinal health records in, 252
  longitudinal population health data in, 252
  machine learning and, 31–32, 35–38, 40
  manufacturers' use of, 100–1
  with new technologies, 3–4
  organization of, 100–1
  in pharmacoepidemiology, 270–71
  pharmacovigilance and, 75–79
    through postmarket analysis, 75
    transformative role of, 75–76
  precision medicine and, 34–36, 101, 105
    traditional approaches to, 34–35
    machine learning and, 35–36
    epistemological shift and, 34–36
  privacy and, 36–40, 109
    losses of, 37–38
    violations of, 38–40
  regulation guidelines for, 4
  epistemology of, 30–34
    causation vs. correlation, 32–33
    theory vs. data, 30–32
    explanation vs. prediction, 34
  small data and, shift from, 15
  on social media, 3
  sorting of, 100–1
  in targeted populations, 99
  in twenty-first century, 26–28
  as valuable commodity, 205
  volume of data with, 252–53

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

Big Data to Knowledge Initiative, 15
bioethics
  autonomy and, 20–22. *See also* Common Rule; Health Insurance Portability and Accountability Act Privacy Rule
  top-down standards for, 23
biological sequence information, 315
biomarkers, 91
biomedical Big Data, 190–91
  genetics research, 190
  HIPAA and, 255–61
  implementation of, 191
biospecimens, 197–99
  duty to share, 215–16, 218, 220–21
  identifiable, 227
  non-identified, 227
black box medicine, 296–98
  benefits of, 297–98
  epistemology of, 35–36
  implementation of, 298
  informed consent and, 299
  intellectual property rights for, 322
  legality of, 295
  medical liability law and, 298
  Precision Medicine Initiative and, 295
  privacy and, 40
  risk-based approach to, 302–3
black box software, 294
body scores, 58
BRAIN Initiative, 15, 19
breaches, of group privacy, 185–86
Breyer, Stephen (Justice), 115

Cancer Moonshot, 15, 19
Caplan, Art, 157
causation, 32–33
  theories of, 32–33
  fairness and, 53–54
  health-related Big Data correlations and, 50–52
  law of, 52–54
CDIA. *See* Consumer Data Industry Association
CDL. *See* Common Data Layout
CDRH. *See* Center for Devices and Radiological Health
CDS products. *See* clinical decision support products
Center for Devices and Radiological Health (CDRH), 292
Centers for Medicare and Medicaid Services (CMS), 1
  under FCA, 73
    claims processing rates, 83
certification, of TPDAs, 147, 154–55
CFR. *See* Code of Federal Regulations
citizen education, 155
Civil Rights Act (1964), U.S., 95
clearinghouses, 138–41
  CDIA, 139
  CRAs and, 139
  under FCRA, 139
clients, for TPDAs, 148
clinical care, under Common Rule, 238–39
clinical decision support (CDS) products, 284, 287–93
  development of
    advances in, 289–90
    failures in, 288–89
  medical liability law and, 300
  new regulatory paradigms, 291–93
  next generation, 291, 294
CMS. *See* Centers for Medicare and Medicaid Services
Code of Federal Regulations (CFR), U.S., 196
collection, of data
  of Big Data, 100–1
    through consumer data, 101–2
    distrust of medical community as factor in, 104
    through EHRs, 98–99, 102–4
    model for, 110–11
  through clearinghouses, 139
  under HIPAA, 257
  by TPDAs, 152–53
    through data requests, 148
collective agency, 188–89
collective identity, 188–89
collectives, 187
Common Data Layout (CDL), 120–21
Common Rule, 20–21, 23–25
  Big Data under, 246–47
    electronic communications and, informed consent in, 246–47
  clinical care under, 238–39
  confidentiality and, 244–46
  control in research under, 244–46
  data access under, 28–29
  data exemptions under, 242–43
  development of, 238–41
    ethics in, 241
    National Commission for Protection of Human Subjects of Biomedical and Behavioral Research and, 238–40
    privacy issues, 239–41
    regulatory structure, 240–41
  duty to share under, 218
  ethical guidelines, 247–49
    during development process, 241

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

Common Rule (cont.)
flexibility of, 247
health research under, 207–8, 238–39
HHS regulations for, 259–60
HIPAA and, 247–48
for identifiable private data, 243–44
under public health law, 245
individual privacy protections under, 223–25
exemptions from, 224
informed consent and, 26, 244–46
Big Data and, through electronic communications, 246–47
privacy and, under U.S. law, 196–97
IRBs and, 244
proactive approach to, 247
problems with, 242–46
distinction between research and non-research activities, 242–44
with number of activities, 242–44
professional standards, 247
public trust elements in, 247–48
regulatory structure of, 248–50
during development process, 240–41
standards, 247
revised versions of, 241
commonwealths, 22
completion technique, 194–95
confidentiality
with Big Data health care research, 255
under Common Rule, 244–46
conscientious objection, to duty to share, 220–21
consent. *See* informed consent
consumer data. *See also* consumer-driven data commons
Big Data through, 101–2
Consumer Data Industry Association (CDIA), 139
Consumer Privacy Bill of Rights (CPBR), U.S., 62, 143
consumer/credit reporting agencies (CRAs), 65–66
clearinghouses and, 139
consumer-driven data commons, 23–26, 29
advantages of, 25
ethical standards of, 25–26
rules of access for, 24
value of, 24
control, in research, 244–46
copyrights, 314–15
of biological sequence information, 315
data selection, 314–15
correlations
Big Data and, 32–33
health-related Big Data and, 46–52
background of, 46–49
causation and, 50–52
failures within, 46–49
hypotheticals in, 46–49
mechanisms and, 47–48
costs, of Big Data health care research, 253
CPBR. *See* Consumer Privacy Bill of Rights
CRAs. *See* consumer/credit reporting agencies

data. *See* Big Data; small data
data access mandates, 154
data analysis. *See also* analytics
in Precision Medicine Initiative, 163
by TPDAs, 148
data brokers
under FCRA, 60
under FTC guidelines, 64
for health-related Big Data, 60–62, 88–89
HIPAA guidelines, 61–62
data collection. *See* collection
data determinism, 58
data manipulation, under FCA, 79–83
as direct false claim, 81–82
as reverse false claim, 82–83
data minimization, 62
data mining, 63
ADA and, 96
pharmacovigilance and, 78
data protection
DPA, 194–95
EU General Data Protection Regulation, 192
for health-related Big Data, 58–60
conservative approach to, 59
FIPPs for, 59
FTC guidelines for, 63–67
reform proposals, 62–65
technology challenges, 59–60
reform proposals
through data minimization, 62
for health-related Big Data, 62–65
through TPDAs, 147
data sharing schemes, 280
under Expert Determination Pathway, 282
database protections, in EU, 315
data-generating patents, 324–36
economic effects of, 329–30
deadweight loss extensions, 329–30
innovation incentives, 329
evolution of, 326–27
genetic disease marker proprietary databases, 326–27
across technological fields, 327
legal consequences of, 327–29
problems with, 330–36
under antitrust rules, 333
disclosure-related issues, 334–35

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

identification of, 330–31
innovation-related issues, 331–34
sui generis protection of, 335
trade secrets and, 327–29
deadweight loss extensions, 329–30
DeCODE, 193–95
DPA and, 194
estimated data in, 193–94
right to not know and, 202
Defend Trade Secrets Act (DTSA), U.S., 318
deidentification, of data
through Expert Determination pathway, 273–74, 278–80
anonymization of data, 281–82
best practices for, 280–82
data sharing under, 282
HIPAA and, 273–75
through Limited Data Set pathway, 274–76, 279–80
through Safe Harbor pathways, 273, 276–80
Department of Health and Human Services (HHS), 259–60
descriptive analytics, 179
diagnostic patents, 312–14
in European Union, 313–14
in U.S., 312–13
difference-making causation, 32–33
dignitary harm, 230–31
direct false claim, 81–82
disabilities, definitions of, 93–96
discrimination
ADA protections against, 71–72
through health-related Big Data use, 58
through redlining, 58
disease modeling, 56–58
disruption model, defined, 70
distrust of medical community, 104
DPA. *See* Icelandic Data Protection Authority
drug labeling, 76–77
misbranding in, 76
DTSA. *See* Defend Trade Secrets Act
duty to share, health-related Big Data
arguments for, 212–21
informed consent in, 214
for patients' property rights, 212–16
reciprocity, 215–21
for biospecimens, 215–16, 218, 220–21
clarification of, 209–12
under Common Rule, 218
conditions for, 209–12
conscientious objection to, 220–21
through EHRs, 209
opt-ins, 211
opt-outs, 211
insurance type classification, 219
IRBs and, 221–22
re-identification in, 215

economic disenfranchisement, from TPDAs, 150–51
EHRs. *See* electronic health records
electronic communication, informed consent through, 246–47
electronic doctors, 266–67
electronic health records (EHRs), 73–74, 269–71
Big Data through, 98–99, 102–4
duty to share through, 209
opt-ins, 211
opt-outs, 211
TPDAs and, 152
Emmanuel, Ezekiel, 74
employers, health-related data for, 86
Employment Retirement Income Security Act (ERISA) (1974), U.S., 69
defined, 114
Gobeille v. Liberty Mutual Insurance Co. and, 113–16
preemption clauses in, 114–15
end of theory claims, 31, 50
epidemic prediction, 56–58
epistemic probabilities, 37
epistemology of big data, 30–34
Equal Credit Protection Opportunity Act, U.S., 66
Equal Pay Act, U.S., 95
ERISA. *See* Employment Retirement Income Security Act
Erlich, Yaniv, 194
ethics
Big Data and, 4, 41
in Common Rule
during development process, 241
guidelines for, 247–49
Expert Determination pathway and, 279–80
Limited Data Set pathway and, 279–80
Safe Harbor pathway and, 279–80
top-down standards, 23
ethnic minorities. *See* minorities
EU General Data Protection Regulation, 192
European Union, intellectual property rights in
algorithm patents, 313–14
database protections in, 315
diagnostic patents, 313–14
regulatory exclusivities, 319
software patents, 313–14
trade secrets, defined, 317
Evans, Barbara, 262
exceptionalism, health research for Big Data and, 206

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

Expert Determination pathway, 273–74, 278–79
anonymization of data, 281–82
best practices for, 280–82
data sharing under, 282
ethical considerations for, 279–80
privacy protections in, 279–80

Faden, Ruth, 217
Fair Credit Reporting Act (FCRA), U.S., 60, 110
clearinghouses under, 139
CRA oversight under, 65–66
FTC and, 66
HIPAA and, 260
Fair Information Practice Principles (FIPPs), 59
FTC and, 63–64
Healthcare Internet of Things and, 143
fairness
law of causation and, 53–54
law of reason and, 53–54
Fallon, Richard, 20
false claims. *See* direct false claim; reverse false claim
False Claims Act (FCA), U.S., 6
amendments to, 80
CMS under, 73
claims processing rates, 83
data manipulation and, 79–83
as direct false claim, 81–82
as reverse false claim, 82–83
historical development of, 80–81
liability under, 81
Medicaid and, 80
Medicare and, 80
pharmacovigilance under, 73
Family Educational Rights and Privacy Act (FERPA) (1974), U.S., 260–61
FCA. *See* False Claims Act
FCC. *See* Federal Communications Commission
FCRA. *See* Fair Credit Reporting Act
FDA. *See* Food and Drug Administration
FDCA. *See* Food, Drug & Cosmetic Act
Federal Communications Commission (FCC), 129, 136
Federal Policy for the Protection of Human Subjects (Common Rule). *See* Common Rule
Federal Trade Commission (FTC), 57
data brokers and, 64
Equal Credit Protection Opportunity Act and, 66
extant powers of, 65–67
FCRA and, 66
FIPPs and, 63–64
health-related Big Data and, protections for, 63–67
Internet of Things device regulation, 129, 136
regulation of privacy laws, 260
Federal Trade Commission Act, U.S., 110
FERPA. *See* Family Educational Rights and Privacy Act
financial institutions, health-related Big Data for, 86
FIPPs. *See* Fair Information Practice Principles
Floridi, Luciano, 159–60, 183–85. *See also* informational privacy
Food, Drug & Cosmetic Act (FDCA), U.S., 81
Food and Drug Administration (FDA)
Big Data and, enforcement guidelines for, 107–9
CDRH guidelines, 292
CDS products regulated by, 284, 287–93
development failures, 288–89
development of, 288–90
medical liability law and, 300
new regulatory paradigms, 291–93
next generation, 291, 294
Internet of Things devices and, regulation of, 129
medical software regulation, 284–88, 301
for black box software, 294
under Draft Software Policy, 285–86
of IVDMIAs, 286–87
mHealth applications and, 134–35
pharmacoepidemiologic studies, 78–79
pharmacovigilance by, 69
SDAs and, 78–79
fraud
health care, statutes against, 74
for overbilling, 74
in health-related Big Data, 56–57
free TPDAs, 151
FTC. *See* Federal Trade Commission

GAIN Act. *See* Generating Antibiotic Incentives Now Act
GDPR. *See* General Data Protection Regulation
Genera Morborum (Linnaeus), 34–35
General Data Protection Regulation (GDPR), 45
TPDAs under, 152
Generating Antibiotic Incentives Now (GAIN) Act (2012), U.S., 319
genetic disease marker proprietary databases, 326–27
Genetic Information Nondiscrimination Act (GINA), U.S., 93–94, 190
genetic testing, 101
genetics research, 190

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

genome sequencing, 101
genomic data flood, 2
GINA. *See* Genetic Information Nondiscrimination Act
Ginsburg, Ruth Bader (Justice), 115
Gobeille v. Liberty Mutual Insurance Co., 113–24
  APCDs and, 116–19
  Department of Labor regulations influenced by, 119–21
  ERISA and, 113–16
  incentives for data sharing after, 122–23
  long-term legal impact of, 115–19
    on health services research, 117–19
    on Medicaid, 118
    on Medicare, 118
    on states' programs and initiatives, 116
  voluntary data contributions by payers after, 121–22
government subsidies, for TPDAs, 150–51
Gramm-Leach-Bliley Act, U.S., 260
group privacy, 176–77, 183. *See also* collectives
  for ad hoc groups, 188
    defined, 187
    identity management for, 185–86, 189–90
  anti-discrimination laws for, 187
  for ascriptive groups, 187
  in biomedical Big Data, 190–91
    genetics research, 190
    implementation of, 191
  breaches of, 185–86
  for collectives, 187
  moderate interpretation of, 186
  right to inviolate personality and, 185–90
  strong interpretation of, 186
  weak interpretation of, 186

Hatch-Waxman Act, U.S., 319
HCUP. *See* Healthcare Cost and Utilization Project
Health Care Cost Institute, 121–22
health care data. *See* health care research; health-related Big Data
health care fraud. *See also* False Claims Act
  Big Data and, 75–79
    through postmarket analysis, 75
    regulatory requirements, 76–77
    transformative role of, 75–76
  through overbilling, 74
  pay and chase model, 79–80
  statutes against, 74
health care research, for Big Data. *See also* deidentification; genetics research
  challenges for, 253–55
    with aggregated data, 254–55
    best practices standards, 254
    confidentiality issues, 255
    linkage of data from multiple sources, 254
  under Common Rule, 207–8, 238–39
  compared to other research uses, 225–35
  cost savings from, 253
  data facilitation in, 205
  data protection for, 206–7
  exceptionalism and, 206
  in *Gobeille v. Liberty Mutual Insurance Co.*, 117–19
  HIPAA and, 206–7
    aggregated data limitations, 258–59
    collaborative research under, 258
    deidentification of data, 273–75
    enhancement strategies for, 261–63
    limited data sets in, 272–73
    sharing observational research, 271–75
  human subjects in, 226–28
    Common Rule standards for, 226–28
    individually identifiable, 226–28
  IRBs and, 228–30
    privacy protections and, societal lapses in, 230
    sensitivity of health information, 229–30
    social media and, 230
  overview of, 252–53
  policy options for, 235–36
  of private information, 228
  professional cooperation in, 337–39
  public trust in, 263
  risk assessment of, 230–35
    administrative burdens of, 232
    application of uniform daily life risks standard, 232–34
    dignitary harm and, 230–31
    mediation of risk in, 234–35
    minimal risk determination, 231–33
    recognition of risk in, 230–31
  volume of data, 252–53
health disparities, 101–6
  among racial and ethnic minorities, 104–5
Health Information Technology for Economic and Clinical Health (HITECH) Act (2009), U.S., 102–3, 269
  HIPAA and, 272
Health Insurance Portability and Accountability Act (HIPAA), U.S.
  Big Data health care research and, 206–7
    aggregated data limitations, 258–59
    collaborations in, 258
    deidentification of data, 273–75
    enhancement strategies for, 261–63
    limited data sets in, 272–73
    sharing observational research, 271–75

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

Health Insurance Portability and Accountability Act (HIPAA), U.S. (cont.)
biomedical data and, 255–61
Common Rule and, 247–48
data brokers under, 61–62
data collection under, 257
data disclosure exceptions, 123
data sharing schemes, 280
draft development of, 255–56
FCRA and, 260
FERPA and, 260–61
HITECH Act and, 272
individual privacy protections under, 224
overview of, 251–52
PHI and, 257–59
reclassification of, 259–60
privacy laws and, 260–61, 269, 279–80
purpose and function of, 261
regulations under, 126, 257–58
reforms of, 259–60
risk assessment and, 257
wearable technology under, 257
Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule, 20–21, 23–25
data access under, 28–29
data brokers under, 61–62
data disclosure exceptions, 123
health-related data and, 90
informed consent in, 26
health records. *See* electronic health records; longitudinal health records
health services research, 117–19
Healthcare Cost and Utilization Project (HCUP), 90
Healthcare Internet of Things (IoT). *See also* Third-Party Data Auditors
CPBR and, 143
design considerations for, 143–46
accordance with existing laws and norms, 145–46
accountability in, 144–45
individual awareness in, 143–44
innovation protections, 146
transparency in, 144–45
FIPPs and, 143
health-related Big Data, 44–46. *See also* deidentification; duty to share; *Gobeille v. Liberty Mutual Insurance Co.*; health care research
APCDs, 112–13
body scores in, 58
commercial use of, 57–58
as commodity, 262
correlations and, 46–52
background of, 46–49
causation and, 50–52
failures within, 46–49
hypotheticals in, 46–49
data brokers for, 60–62, 88–89
HIPAA guidelines, 61–62
data protection policies for, 58–60
conservative approach to, 59
FIPPs for, 59
FTC guidelines for, 63–67
reform proposals, 62–65
technology challenges, 59–60
debate over, 56–58
decrease in antimicrobial resistance, 56–57
defined, 44–45, 98
by GDPR, 45
deprecation of, 59–60
discriminatory uses of, 58
disease modeling, 56–58
disease prediction and, 91–92
for employers, 86
epidemic prediction, 56–58
expansion of, 2–3
for financial institutions, 86
fraud in, 56–57
FTC guidelines for, 63–67
after *Gobeille v. Liberty Mutual Insurance Co.*, 122–23
high-risk patients and, identification of, 56–57
under HIPAA Privacy Rule, 90
for interested parties, 86–87
Internet of Things and, 45–46
law of causation and, 52–54
fairness and, 53–54
law of reason and, 52–54
fairness and, 53–54
legal implications of, 45
for marketing and advertising, 86
misuse of, 56
from non-biomedical sources, 2–3
through open data sources, 89–90
patients' property rights for, 212–16
pharmacovigilance and, 56–57
studies of, 3
privacy protections for, 90
professional cooperation strategies with, 337–39
as public good, 262
public health surveillance and, 56–58
regulatory arbitrage and, 60–62
through social media, 87–88
subsumption approach, 5–6
through wellness programs, 88

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

HHS. *See* Department of Health and Human Services
high-risk patients, identification of, 56–57
HIPAA. *See* Health Insurance Portability and Accountability Act
HIPAA Privacy Rule. *See* Health Insurance Portability and Accountability Act Privacy Rule
HITECH Act. *See* Health Information Technology for Economic and Clinical Health Act
Hobbes, Thomas, 22
hospital referral regions (HRRs), 121–22
human subjects
  in Big Data health care research, 226–28
    Common Rule standards for, 226–28
    individually identifiable, 226–28
  National Commission for Protection of Human Subjects of Biomedical and Behavioral Research, 238–40
hypothetico-deductive method, 30–31

Icelandic Data Protection Authority (DPA), 194–95
identifiable biospecimen, 227
identifiable private data, under Common Rule, 243–44
  public health law and, 245
identifiable private information, 227
identity
  active breaches of, 185
  of ad hoc groups, 185–86, 189–90
  in analytics, ethical significance of, 177–83
    offline, 179
    personalization systems, 181–82
    profiling, 179–82
    shared ownership of, 180–81
  collective, 188–89
  informational, 183
  passive breaches of, 185–86
identity-constitutive privacy, 183
in vitro diagnostic multivariate index assays (IVDMIAs), 286–87
individual autonomy. *See* autonomy
individual awareness
  in Healthcare Internet of Things design, 143–44
  TPDAs and, 149
individual privacy, protections for
  additional structures for, 223–24
  for biospecimens, 224
  under Common Rule, 223–25
    exemptions from, 224
  under HIPAA, 224
  historical development of, 223
  IRBs and, 223–25
  in U.S., 225
informational identity, 183
informational privacy, 176, 183–85
informed consent
  in analytics, 185
  Big Data and, 5
    through electronic communications, 246–47
  black box medicine and, 299
  under Common Rule, 26, 244–46
    Big Data and, through electronic communications, 246–47
  in duty to share, 214
  in HIPAA Privacy Rule, 26
  privacy and, under U.S. law, 196–202
    of biospecimens, 197–99
    in CFR, 196
    under Common Rule, 196–97
    denial of consent, 201
    individual perspectives on, 199–202
    under NPRM, 197–200
innovation protections
  in Healthcare Internet of Things design, 146
  in TPDAs, 150
Institutional Review Boards (IRBs), 20–21
  Big Data health research for, 228–30
    privacy protections, societal lapses in, 230
    sensitivity of health information, 229–30
    on social media, 230
  Common Rule and, 244
  duty to share and, 221–22
  individual privacy protections, 223–24
  right not to know and, 203–4
integrated Big Data sets, 256
intellectual property rights (IPRs), Big Data and
  algorithm patents, 312–14
    in European Union, 313–14
    in U.S., 312–13
  antitrust rules, 320–21
  for black box medicine, 322
  challenges with, 311
  copyrights, 314–15
    of biological sequence information, 315
    data selection, 314–15
  database protections, in EU, 315
  diagnostic patents, 312–14
    in European Union, 313–14
    in U.S., 312–13
  for large research infrastructures, 321–22
  overview of, 312–19
  for private sector use of public data, 322–23

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

intellectual property rights (IPRs), Big Data and (cont.)
regulatory exclusivities, 318–19
in European Union, 319
in U.S., 319
software patents, 312–14
in European Union, 313–14
in U.S., 312–13
for specific applications, 321–23
for specific areas of science, 321–23
sui generis rights, 312–19
for data-generating patents, 335
for SysBio, 321
trade secrets, 316–18
EU definition of, 317
in U.S., 318
international law, privacy in, 176
Internet of Things (IoT) devices. *See also* Healthcare Internet of Things; mobile Health applications
ethical frameworks for, 125
FCC regulation of, 129, 136
FDA regulation of, 129
FTC regulation of, 129, 136
health-related Big Data and, 125
legal frameworks for, 125
regulatory frameworks for, 125
IPRs. *See* intellectual property rights
IRBs. *See* Institutional Review Boards
IVDMIAs. *See* in vitro diagnostic multivariate index assays

Kant, Immanuel, 20
Kennedy, Anthony (Justice), 114–15
Kyllo v. United States, 39–40

labeling. *See* drug labeling
laboratory developed tests (LDTs), 286–87
Lacks, Henrietta, 215
large research infrastructures, 321–22
LDTs. *See* laboratory developed tests
legal rights, 176
legislation, for health-related data. *See specific legislation and acts*
LHRs. *See* longitudinal health records
liability law. *See* medical liability law
Lifeline program, 110–11
Limited Data Set pathway, 274–76
ethics and, 279–80
privacy protections in, 279–80
Linnaeus, Carolus, 34–35
longitudinal health records (LHRs), 252
longitudinal population health data (LPHD), 252

machine learning, 31–32, 35–38, 40
marketing, health-related Big Data for, 86
mechanisms, 47–48
accountability, 149–50
transparency, 149–50
Medicaid. *See also* Centers for Medicare and Medicaid Services
FCA and, 80
after *Gobeille v. Liberty Mutual Insurance Co.*, 118
medical devices. *See* Internet of Things devices; mobile Health applications
Medical Electronic Data Technology Enhancement for Consumers Health (MEDTECH) Act, U.S., 134
medical liability law, 298–304
for black box medicine, 298
CDS products, 300
future recommendations for, 304–5
for health care enterprises, 303–4
medical malpractice by providers, 299–303
patient recovery under, 298–99
purpose of, 298
medical software, FDA regulation of, 284–88, 301. *See also* clinical decision support products; Internet of Things devices; mobile Health applications
for black box software, 294
under Draft Software Policy, 285–86
of IVDMIAs, 286–87
Medicare. *See also* Centers for Medicare and Medicaid Services
FCA and, 80
after *Gobeille v. Liberty Mutual Insurance Co.*, 118
medicine. *See* black box medicine
MEDTECH Act. *See* Medical Electronic Data Technology Enhancement for Consumers Health Act
minorities, racial and ethnic
distrust of medical community by, 104
health disparities among, 104–5
MMAs. *See* mobile medical applications
mobile Health (mHealth) applications
through apps, 132
clearinghouses and, 138–41
CDIA, 139
data collection in, 139
regulation of, 139
practical concerns with, 135–38
quantified-self, 131
regulation of, 129
concerns over, 134–35
by FDA, 134–35

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

smartphones, 130–34
software platforms for, 133
wearables, 131–32
under HIPAA, 257
mobile medical applications (MMAs), 133
moderate interpretation, of group privacy, 186
moral informational privacy, 176
moral rights, 176

NAHDO. *See* National Association of Health Data Organizations
naïve inductivism, 31
Narayanan, Arvind, 194
NASHP. *See* National Academy for State Health Policy
natalizumab, 118, 270
National Academy for State Health Policy (NASHP), 120
National Association of Health Data Organizations (NAHDO), 120
National Commission for Protection of Human Subjects of Biomedical and Behavioral Research, 238–40
National Institutes of Health (NIH), 107, 198–99
National Research Act, U.S., 242
National Research Council, 235
next generation CDS products, 291, 294
NIH. *See* National Institutes of Health
Nissenbaum, Helen, 39
non-identified biospecimens, 227
non-identified information, 227
norm of common purpose, 19–20
Notice of Proposed Rulemaking (NPRM), 197–200

Obama, Barack, 319
Obermeyer, Ziad, 74
objective probabilities, 37–38
Office for Civil Rights (OCR), of Department of Health and Human Services, 129
Office for Human Research Protections (OHRP), 244
Office of the National Coordinator for Health Information Technology (ONC), 129
offline identity, 179
OHCAs. *See* organized health care arrangements
OHRP. *See* Office of Human Research Protections
Okediji, Ruth L., 322–23
ONC. *See* Office of the National Coordinator for Health Information Technology
open data sources, 89–90
opt-ins, duty to share, 211
opt-outs, duty to share, 211
organized health care arrangements (OHCAs), 258
Orphan Drug Act, U.S., 319

Parasidis, Efthimios, 100
passive breaches of identity, 185–86
patents. *See* algorithm patents; data-generating patents; diagnostic patents; software patents
patienthood, 189
patients' property rights, for health-related Big Data, 212–16
pay and chase model, 79–80
PCAST. *See* President's Council of Advisors on Science and Technology
pediatric care, discrepancies in, 117
Personal Genome Project, 229
personalization systems, 181–82
pharmacoepidemiology
Big Data in, 270–71
studies in, 78–79
pharmacovigilance. *See also* False Claims Act
Big Data and, 75–79
through postmarket analysis, 75
transformative role of, 75–76
data mining and, 78
defined, 77–78
under False Claims Act, 73
by FDA, 69
health-related Big Data and, 56–57
studies of, 3
SDAs and, 78–79
studies of, 3
World Health Organization on, 79
PHI. *See* protected health information
Pietsch, Wolfgang, 31
post-approval research pathways, 274–79
Expert Determination, 273–74, 278–79
anonymization of data, 281–82
best practices for, 280–82
data sharing under, 282
ethical considerations for, 279–80
privacy protections in, 279–80
Limited Data Set, 274–76
ethics and, 279–80
privacy protections in, 279–80
Safe Harbor, 273, 276–78
ethical considerations for, 279–80
privacy protections in, 279–80
precision medicine
Big Data and, 34–36, 101, 105
traditional approaches to, 34–35
machine learning and, 35–36
epistemological shift and, 34–36
genetic testing and, 101
genome sequencing and, 101
NIH and, 107

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

Precision Medicine Initiative, 15, 19, 106–7
  black box medicine and, 295
  defined, 271
  methods of, 161–63
    data analysis, 163
    data collection, 162–63
    for participants, 161–62
  results, 163–72
    participant characteristics, 163–64
  risk assessment in, 163–72
    for longitudinal study design, 171–72
    of nature of genetic information, 170–71
    overview of, 172–74
    for permitted but unwanted use of information, 167–70
    for unintended access to identity, 163–67
prediction modeling, 117
predictive analytics, 182
prescriptive analytics, 179
President's Council of Advisors on Science and Technology (PCAST), 63
Price, Nicholson, 291, 312, 322. *See also* black box medicine
privacy. *See also* group privacy; Health Insurance Portability and Accountability Act Privacy Rule; individual privacy
  under ADA, 260
  Big Data and, 36–40, 109
    losses of privacy, 37–38
    violations of privacy, 38–40
  for Big Data health research, IRBs and, 230
  under Common Rule, 239–41
  contextual integrity theory, 39
  in Expert Determination pathway, 279–80
  family resemblance theory, 39
  identity-constitutive, 183
  informational, 176, 183–85
  informed consent and, under U.S. law, 196–202
    of biospecimens, 197–99
    in CFR, 196
    under Common Rule, 196–97
    denial of, 201
    individual perspectives on, 199–202
    under NPRM, 197–200
  in international law, 176
  in *Kyllo v. United States*, 39–40
  in Limited Data Set pathway, 279–80
  right to inviolate personality and, 183–85
    group privacy and, 185–90
  technological challenges to, 256
  top-down standards for, 23
Privacy Act (1974), U.S., 59, 240
privacy laws
  ADA, 260
  FCRA, 60, 110
    clearinghouses under, 139
    CRA oversight under, 65–66
    FTC and, 66
    HIPAA and, 260
  FERPA, 260–61
  FTC regulation of, 260
  Gramm-Leach-Bliley Act, 260
  HIPAA and, 260–61, 269, 279–80
  HITECH Act, 102–3, 269
  PHI under, 257–59
    reclassification of, 259–60
private information, health research for, 228
profiling, of identity, 179–82
protected health information (PHI), 257–59
  reclassification of, 259–60
protection. *See* data protection
public accommodations, under ADA, 92–93
public good, health-related Big Data as, 262
public health law, 245
public health surveillance, 56–58
public trust. *See also* distrust of medical community
  in Big Data health care research, 263
  in Common Rule, 247–48

racial minorities. *See* minorities
Racketeer Influenced and Corrupt Organizations Act (RICO), U.S., 81
Ramirez, Edith, 138
reason, law of, 52–54
  fairness and, 53–54
reasonable expectation of privacy, 39
reciprocity argument, 215–21
redlining, through health-related Big Data, 58
regulations, on data
  adjustment of, 6
  Big Data and, 4
    for health care fraud, 76–77
  under Common Rule, 248–50
    during development process, 240–41
    standards for, 247
  under GDPR, 45
    TPDAs under, 152
  after *Gobeille v. Liberty Mutual Insurance Co.*, 119–21
  health-related Big Data, 60–62
  under HIPAA, 126, 257–58
    reforms of, 259–60
  Internet of Things devices, 129, 136

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

through mHealth applications, 129
clearinghouses, 139
concerns over, 134–35
by FDA, 134–35
under SOFTWARE Act, 134
regulatory arbitrage, 60–62
regulatory exclusivities, 318–19
in European Union, 319
in U.S., 319
Rehabilitation Act (1973), U.S., 94
reidentification, in duty to share, 215
relationality, defined, 159
reports, by TPDAs, 148–49
aggregate, 148–49
research. *See also* genetics research; health care research
defined, 243
reverse false claim, 82–83
RICO. *See* Racketeer Influenced and Corrupt Organizations Act
right not to know, 202–4
ACMG recommendations, 202–3
DeCODE and, 202
IRB members and, 203–4
limitations of, 204
right to inviolate personality, 183–85
group privacy and, 185–90
Riley, Margaret Foster, 205
risk assessment. *See also* high-risk patients
of Big Data health research, 230–35
administrative burdens of, 232
application of uniform daily life risks standard, 232–34
dignitary harm and, 230–31
mediation of risk, 234–35
minimal risk determination, 231–33
recognition of risks, 230–31
HIPAA and, 257
in Precision Medicine Initiative, 163–72
for longitudinal study design, 171–72
of nature of genetic information, 170–71
overview of, 172–74
for permitted but unwanted use of information, 167–70
for unintended access to identity, 163–67
Rorty, Richard, 22

Sachs, Rachel, 312
Safe Harbor pathway, 273, 276–78
ethical considerations for, 279–80
privacy protections in, 279–80
Schauer, Fred, 256
scientific inquiry and knowledge, Big Data as influence on, 30–34
causation vs. correlation, 32–33
theory vs. data, 31
explanation vs. prediction, 34
SDAs. *See* signal detection algorithms
security, TPDA limitations, 152–53
self-service TPDAs, 151
self-subsidized TPDAs, 151
Sensible Oversight for Technology which Advances Regulatory Efficiency (SOFTWARE) Act, U.S., 134
sensitivity of health information, 229–30
Sentinel Initiative, 100
Sentinel System, 6
shared ownership of identity, 180–81
The Signal and the Noise (Silver), 51
signal detection algorithms (SDAs), 78–79
Silver, Nate, 51
Skopek, Jeffrey, 202, 210
small data, Big Data and, 15
social media
Big Data health research on, 230
Big Data on, 3
health-related Big Data through, 87–88
software. *See* medical software
SOFTWARE Act. *See* Sensible Oversight for Technology which Advances Regulatory Efficiency Act
software patents, 312–14
in European Union, 313–14
in U.S., 312–13
solidarity, civic
autonomy and, 22
development of, 26–28
Solove, Dan, 39
Steffanson, Kari, 202
strong interpretation, of group privacy, 186
subsumption approach, 5–6
sui generis rights, 312–19
for data-generating patents, 335
Sweeney, Latanya, 229
systems biology (SysBio), 321

technology. *See also* Internet of Things devices; medical software; mobile Health applications
Big Data and, 3–4
data protection challenges, for health-related Big Data, 59–60
under HITECH Act, 102–3
under MEDTECH Act, 134
ONC and, 129
PCAST and, 63

© in this web service Cambridge University Press www.cambridge.org

CAMBRIDGE

Cambridge University Press
978-1-107-19365-9 — Big Data, Health Law, and Bioethics
Edited by I. Glenn Cohen , Holly Fernandez Lynch , Effy Vayena , Urs Gasser
Index
More Information

technology (cont.)
under SOFTWARE Act, 134
TPDAs and, 147
Third-Party Data Auditors (TPDAs), 142–43, 146–55
benefits of, 147
certification of, 147, 154–55
client hiring of, 148
considerations of, 150–54
data analysis by, 148
data collection by, 152–53
through data requests, 148
data policy considerations, 149–50
accordance with existing laws, 150
accountability mechanisms, 149–50
for individual awareness, 149
for innovation protections, 150
transparency mechanisms, 149–50
data protection through, 147
defined, 146–47
EHR systems and, 152
free, 151
under GDPR, 152
government subsidies for, 150–51
limitations of, 150–54
economic disenfranchisement as, 150–51
with expanding amounts of data, processing issues, 151–52
security issues, 152–53
technical, 152
in user education, 153–54
policy goals of, 147
policy recommendations for, 154–55
for certification process, 154–55
for citizen education, 155
data access mandates, 154
for regulations process, 154–55
report formulation by, 148–49
through aggregate reports, 148–49
self-service, 151
as self-subsidized, 151
setup completion by, 147
technological advances and, 147
TPDAs. *See* Third-Party Data Auditors
trade secrets, 316–18
data-generating patents and, 327–29
EU definition of, 317
in U.S., 318
transparency
as Healthcare Internet of Things design consideration, 144–45
in TPDA mechanism, 149–50
21st Century Cures Act, U.S., 271
Tysabri. *See* natalizumab

uniform daily life risks standard, 232–34
Uniform Trade Secrets Act, U.S., 318
United States (U.S.). *See also* Americans with Disabilities Act; False Claims Act; Federal Trade Commission; Food and Drug Administration
algorithm patents in, 312–13
CFR in, 196
Consumer Privacy Bill of Rights, 62
CPBR, 62, 143
diagnostic patents, 312–13
GINA, 93–94
health-related Big Data and
FTC protections and, 63–67
under HIPAA Privacy Rule, 90
HHS, 259–60
HIPAA Privacy Rule, 20–21, 23–25
data access under, 28–29
data brokers under, 61–62
health-related Big Data under, 90
informed consent in, 26
informed consent in, privacy and, 196–202
of biospecimens, 197–99
in CFR, 196
under Common Rule, 196–97
denial of, 201
individual perspectives on, 199–202
under NPRM, 197–200
regulatory exclusivities in, 319
RICO, 81
software patents in, 312–13
trade secrets in, 318
user education, TPDAs and, 153–54

Venter, Craif, 195–96
voluntary data contributions by payers, 121–22

weak interpretation, of group privacy, 186
wellness programs, health-related Big Data through, 88
Wertheimer, Alan, 216–17
World Health Organization, 79

© in this web service Cambridge University Press www.cambridge.org